An­oth­er new man­u­fac­tur­ing site for NC; Bio­Cen­triq ac­quired by South Ko­re­an com­pa­ny

En­zy­vant will ex­pand its re­gen­er­a­tive med­i­cine man­u­fac­tur­ing with a new fa­cil­i­ty in North Car­oli­na’s Re­search Tri­an­gle Park area.

The build­ing of the 25,972-square-foot site will start this sum­mer and wrap up around the end of 2024. It will be lo­cat­ed in Mor­risville, NC.

“I am very pleased about the nov­el ca­pa­bil­i­ties this new man­u­fac­tur­ing fa­cil­i­ty will bring to En­zy­vant and look for­ward to the progress ahead as we look to re­al­ize ef­forts,” said Myr­tle Pot­ter, CEO of Sum­i­to­vant, the hold­ing com­pa­ny of En­zy­vant. “This is a great ex­am­ple of three mem­bers of the Sum­it­o­mo Phar­ma fam­i­ly of com­pa­nies work­ing seam­less­ly to­geth­er to ad­dress the most press­ing is­sues af­fect­ing pa­tients and fam­i­lies with the high­est un­met med­ical needs.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER